Halozyme announces CRADA with NIAID for ENHANZE® drug delivery technology
Halozyme announced a CRADA with the National Institute of Allergy and Infectious Diseases' Vaccine Research Center enabling the VRC's use of Halozyme's ENHANZE® drug delivery technology to develop subcutaneous formulations of bnAbs against HIV for HIV treatment. June 25, 2019